Welcome to the November 2020 edition of the Site Engagement newsletter. This newsletter is dedicated to keeping you informed of news and trends as it relates to site engagement within clinical development.
In this edition, read insights and updates from PRA’s Site Engagement Team. We explore the role of Clinical Trial Liaisons and how their work benefits clinical trial design and helps unite client teams that work with PRA. Also covered is an innovative SCD treatment method focused on genetic editing with CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) DNA and Cas (CRISPR-associated) enzymes.
Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes
Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process…
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.
Easing the Rare Disease Patient’s Burden in Clinical Trials with Innovative Technology
In this webinar, you will learn how technology can influence rare disease clinical study design, increase the speed of research and thereby reduce…